This announcement is a separate document:
宏源药业：上海市通力律师事务所关于湖北省宏源药业科技股份有限公司2023年年度股东大会的法律意见书
Hubei Hongyuan Pharmaceutical Technology: Legal Opinion of Shanghai Tongli Law Firm on the 2023 Annual General Meeting of Shareholders of Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.